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Abstract 
To accelerate our endeavors to overcome cancer, Chinese Journal of Cancer has launched a program of publishing 150 
most important questions in cancer research and clinical oncology. In this article, 10 more questions are presented 
as follows. Question 15: Can tumor-induced erythrogenesis provide qualified red blood cells for carrying oxygen to 
distant organs? Question 16: Can we overcome tumor resistance to platinum-containing antineoplastic drugs by 
activating the sensitivity factors in the tumor? Question 17: How can a cancer cell stay dormant for years? Question 18: 
Why do cancer cells use distinct transcriptomic and proteomic programs to reach the same metastatic phenotype? 
Question 19: Why do some cancers regress spontaneously? Question 20: What are the regulatory mechanisms occur-
ring in donor cells that determine selective sorting of biological content into vesicles and their biological conse-
quences in recipient cells? Are the genetic transfer and exchange of biological messages between cells transient? Is 
the phenotypic manipulation of recipient cells temporary or prolonged and persistent? If extracellular vesicles possess 
immune-modulatory potential, how could they be exploited for immune interventions and cancer immunotherapy? 
Presumably the cargo of extracellular vesicles reflects the cells of their origin and can be used for cancer diagnosis, 
how could the uniform/stringent capture criteria be met universally for applying EVs in point-of-care diagnostics for 
cancer patients? Question 21: Can we use self-sampling technologies to monitor the tumor genetic alterations for 
more precise targeted therapy? Can we cure a heterogeneous tumor by sequentially targeting the driver molecules? 
Question 22: Can we postpone the onset of non-infection-related cancers? Question 23: How many types of cells 
can jointly form the tumor vasculature to provide blood supply for tumor progression? Question 24: How tumor cells 
transmit their epigenetic features to daughter cells and maintain the malignant phenotype?
Keywords: Erythrogenesis, Platinum-containing antineoplastic drugs, Dormancy, Molecular mechanisms, 
Spontaneous tumor regression, Self-sampling technology, Non-infection-related cancer, Tumor angiogenesis, 
Epigenetic feature
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To accelerate our endeavors to overcome cancer, Chi-
nese Journal of Cancer has launched a program of pub-
lishing 150 most important questions in cancer research 
and clinical oncology [1], with the first 14 questions been 
published in the last three issues [2–4]. In this article, 
Questions 15–24 are selected and presented. Chinese 
Journal of Cancer is still open to collect more key ques-
tions in cancer research and clinical oncology. Please 
send us your thoughtful questions to Ms. Ji Ruan via 
email: ruanji@sysucc.org.cn.
Question 15: Can tumor‑induced erythrogenesis 
provide qualified red blood cells for carrying 
oxygen to distant organs?
Background and implications
It has been confirmed that some tumor cells can express 
erythropoietin and its receptor. Moreover, when we 
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examine the tissue structures of clear cell renal cell carci-
noma and hepatocellular carcinoma, numerous red blood 
cells in different maturation phases characterized by the 
cellular shapes could be observed. It is not surprising that 
the kidney and liver are initial organs for erythrogenesis 
during embryonic development. It is highly possible that 
solid tumors in these organs could generate red blood 
cells through the mechanism very different from that of 
typical erythrogenesis in the bone marrow. A very inter-
esting question following the confirmation of tumor-
induced erythrogenesis would be about how good those 
tumor-generated red blood cells are in terms of function-
ing as oxygen carriers. The exploration in this direction 
might be able to open a new field on using animal tumor 
models to robustly generate a large amount of red blood 
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Question 16: Can we overcome tumor resistance 
to platinum‑containing antineoplastic drugs 
by activating the sensitivity factors in the tumor?
Background and implications
Platinum-containing antineoplastic drugs are chemothera-
peutic agents to treat almost 50% of cancer patients. As the 
first member of this family, cisplatin has been used in com-
bination chemotherapy for multiple tumor types. Initial 
therapeutic effects of platinum-containing antineoplastic 
drugs are usually high but cisplatin-resistant tumors will 
inevitably relapse, which happens in the majority of can-
cer patients. Many research teams have been exploring the 
resistant mechanisms for cisplatin treatment in the past 
several decades without clinically significant breakthrough.
We are thinking another way round: Could we enhance 
the therapeutic effects of platinum-based antineoplastic 
drugs by activating the sensitivity factors in the tumor? 
Obviously, the identification of sensitivity factors from 
sable cellular models is therefore critical to answer this 
question. The feasibility of this exploration has been pre-
liminary verified. We have established a super-sensitive 
cellular clone to cisplatin treatment, S16, from its paren-
tal nasopharyngeal carcinoma cell line CNE2. Moreover, 
by using first-generation microarray technology, aspara-
gine synthetase and matrix metalloproteinase 19 have 
been identified and functionally validated to be sensitiv-
ity factors for cisplatin treatment. How to activate the 
sensitivity mechanisms inside a solid tumor could be the 
main issue before clinical benefit could be obtained.
The implications of answering this question include 
enhancing the efficacy of platinum-containing antineo-
plastic drugs, prolonging the survival of cancer patients, 
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Question 17: How can a cancer cell stay dormant 
for years?
Background and implications
Dormancy is very common in nature, in particular in the 
vegetable world where plant seeds can be dormant for 
years and only become to grow again after being planted.
This important biological property also allows a few 
neoplastic cells to survive in otherwise asymptomatic 
patients for years. The consequences are recurrence of 
the disease many years after the successful treatment of 
the primary tumor.
Dormancy has been proposed to be maintained by 
several different ways, e.g., by special cancer stem cells, 
immune surveillance, or a mitotic blockage; however, the 
full comprehension of its biology is still eluding us.
A better understanding of dormancy could lead to a 
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Question 18: Why do cancer cells use distinct 
transcriptomic and proteomic programs to reach 
the same metastatic phenotype?
Background and implications
Transcriptomic and proteomic profiles of metastases ver-
sus primary tumors have been compared by several inves-
tigators. Profoundly distinct profiles have been revealed 
in most cases, with trends for similarity between pairs of 
metastases and primary tumors from individual patients. 
However, rare tight-matches were revealed even across 
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different metastases originating from an individual tumor. 
Next-generation sequencing confirmed the complexity 
of such a scenario. These findings suggest distinct, albeit 
self-supporting, control modules for metastatic spreading.
Determining the underlying molecular mechanisms 
may be very helpful for a better understanding of the 
metastatic process. It may also help avoiding misleading 
classifications of metastatic factors. Ultimately, it may 
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Question 19: Why do some cancers regress 
spontaneously?
Background and implications
Spontaneous tumor regression (STR) is one of the most 
fascinating phenomena observed in medical sciences. 
The first classic monograph on STR was laid by Tilden C. 
Everson and Warren H. Cole in 1956. Colorectal cancers, 
malignant melanomas, renal cell carcinomas, and some 
head and neck cancers are known to regress on their own. 
Various mechanisms have been postulated for STR, such 
as the induction of differentiation, apoptosis, tumor necro-
sis, and immunological, hormonal, psychological, and epi-
genetic mechanisms. The intra-tumoral immune reaction 
in the evolution of cancer is known; the hypothesis that 
cancer development is strictly controlled by host’s immune 
reaction has also been well established. The idea is to iden-
tify the underlying intra-tumoral response(s) in cancers 
which fully responded to standard treatment(s), without 
long-term recurrence, and compare the intra-tumoral 
responses in residual disease and recurrences. This 
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Question 20: Question (1): What are the 
regulatory mechanisms occurring in donor cells 
that determine selective sorting of biological 
content into vesicles and their biological 
consequences in recipient cells? Question 
(2): Are the genetic transfer and exchange 
of biological messages between cells transient? 
Is the phenotypic manipulation of recipient 
cells temporary or prolonged and persistent? 
Question (3): If extracellular vesicles possess 
immune‑modulatory potential, how could they be 
exploited for immune interventions and cancer 
immunotherapy? Question (4): Presumably 
the cargo of extracellular vesicles reflects the 
cells of their origin and can be used for cancer 
diagnosis, how could the uniform/stringent 
capture criteria be met universally for applying EVs 
in point‑of‑care diagnostics for cancer patients?
Background and implications
Extracellular vesicles (EVs) are nano-sized vesicles 
(exosomes and microvesicles) secreted by almost every 
cell type under both normal and pathologic conditions. 
EVs contain a variety of proteins such as transcription 
factors as well as nucleic acids such as DNA and non-
coding regulatory RNAs (1, 2). Exosomes are originated 
from endocytic compartments (3), relevantly reflecting 
the cytoplasmic content of their parent cells; microvesi-
cles are shed directly from plasma membrane, com-
paratively reflecting the biology of cell surfaceome. It is 
important to consider that the molecular content and the 
secreted levels of EVs are differentially reflected in each 
cancer type and grade, making EVs a potential source of 
cancer biomarkers (3, 4).
Extracellular vesicles act as conveners of intercellular 
communication by exchanging biological information 
between cells (5–7) and are largely implicated in deter-
mining cell fates (8). Based on their inherent capabil-
ity of transferring regulatory elements, EVs may elicit a 
newly evolved mechanism of trans-regulation between 
cells and confer genomic instability in recipient cells (1). 
The oncogenic content of EVs transferred from cancer 
cells to normal recipient cells could consequently induce 
malignant phenotypes (9–11). In a similar way, EVs could 
mediate an intercellular transfer of phosphatase and ten-
sin homolog (PTEN)-targeting microRNAs to primary 
tumor cells in order to bypass tumor suppressor check-
point and enable primary tumor cells to metastasize 
(12). As such, the EV-mediated dissemination of bioac-
tive content contributes to cell phenotypic transitions, 
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immune modulation, and re-shaping of tumor microen-
vironment (13). The most profound input of cancer-asso-
ciated EVs is their participation in pre-metastatic niche 
formation by enabling cells to mobilize at new regions 
(14, 15). As such, EVs from various tumor types fore-
cast organ-specific metastasis (organotropism) by pref-
erentially fusing at their predicted destinations in target 
organs through EV-linked distinct integrins (16). Thus, 
EVs promote tumor organotropic metastasis and prepare 
favorable pre-metastatic niche for future metastasis.
Since cancer needs successful co-option with extra-
cellular environment, tumor-derived EVs can condition 
tumor microenvironment for successful co-option of 
cancer cells in a given niche (12). For this, EVs trans-
port pro-angiogenic growth factors that cope with 
nutrient requirements in microenvironment and favor 
the formation of blood vessels (17), or may undergo 
vessel co-option. It is tempting to escalate that tumor 
cells have evolved yet another mean of co-option 
through suppressing anti-tumor immune cells by 
secreting EVs loaded with immune-suppressing ligands 
(18). In fact, EVs carrying such ligands interact with 
corresponding receptors presented on immune cells 
and induce suppression or apoptosis of T cells and nor-
mal killer cells. This mechanism facilitates cancer cells 
to co-exist in tumor microenvironment by suppressing 
anti-tumor immune cells (18). Thus, given all observa-
tions together, EVs facilitate stochastic patterns of can-
cer physiology.
Despite multifaceted roles of EVs in cancer biology, some 
important questions about their regulatory mechanisms 
and their clinical applications are yet to be answered. On 
the biotech front, the answers to the above questions will 
improve the way of designing more precise therapeutic 
strategy for cancer patients. Collective efforts from aca-
demia and biotech industries are expected to translate EVs 
into a platform of innovative and personalized therapies.
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Question 21: Question (1): Can we use 
self‑sampling technologies to monitor the 
tumor genetic alterations for more precise 
targeted therapy? Question (2): Can we cure a 
heterogeneous tumor by sequentially targeting 
the driver molecules?
Background and implications
Solid tumors are heterogeneous in nature, and each por-
tion of the tumor might rely on different signaling path-
ways for growth and spread. Moreover, tumor cells have 
a capacity to develop resistance to a single molecule-tar-
geted agent via the up-regulation of the partially inhabited 
pathway, mutation of the target gene, or activation of alter-
native pathway. However, it is hypothesized that driver 
molecules for tumor cell survival and spread are timely 
and spaciously existing. Clearly, a dynamic monitoring on 
tumor genetic alterations to indentify the driver molecules 
is needed to test this hypothesis and to improve therapeu-
tic design. For practicable reason, self-sampling technolo-
gies can facilitate the dynamic monitoring in an economic 
way. The biological samples for self-sampling could be any 
types of body fluid or a drop of blood which are easy to 
collect and preserve. Answering the above-mentioned 
questions will further improve our precision medical prac-
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Question 22: Can we postpone the onset 
of non‑infection‑related cancers?
Background and implications
The formation of approximately two-thirds of cancers 
in all types has no close relationship with infection. The 
etiology of these cancers is mostly undetermined, while 
a significant portion of them is thought to be resulted 
from genetic susceptibility. Two perfect examples of 
genetic susceptibility are adenomatosis polyposis coli 
(APC)-mutated colorectal cancer and breast cancer early 
onset 1/2 (BRCA1/2)-mutated breast cancer. Although 
the genetic susceptibility exists on day one of birth, the 
cancers usually occur in the mid-life of the patients, giv-
ing the hosts several decades of cancer-free survival. In 
2010, I hypothesized that there should be a postponing 
mechanism in the host to delay the cancer onset. I named 
the key molecules for delaying cancer onset as “postpon-
ers.” If we could amplify the to-be-validated postponing 
mechanism, we probably can postpone the cancer onset 
to a late-life period of the patients, providing them sev-
eral more decades of cancer-free survival. Moreover, 
if the postponing efforts are more profound, the hosts 
might not die of cancer in their whole life, avoiding 
those prophylactic yet destructive medical approaches to 
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Question 23: How many types of cells can jointly 
form the tumor vasculature to provide blood 
supply for tumor progression?
Background and implications
The growth and spread of a solid tumor usually depend 
on the establishment of effective vasculature system 
inside and adjacent to the tumor. A classical concept 
is that tumor angiogenesis is resulted from the pro-
liferation and migration of peripheral differentiated 
endothelial cells, with spouting angiogenesis to be the 
most frequently studied pattern of tumor angiogenesis. 
Another important source for forming tumor vascula-
ture is cycling endothelial progenitor cells from the bone 
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marrow, and the lining of endothelial progenitor cells that 
forms blood conduits is named vasculogenesis. Recently, 
the concept of vessel co-option, hijacking the blood ves-
sels in the normal tissue surrounding the tumor, has 
been recognized to be critical in forming the vasculature 
of primary tumor and secondary metastatic tumor. The 
process of vessel co-option is usually accompanied by 
remodeling of the vessels adjacent to the tumor prior to 
being co-opted, as well as the co-opted vessels inside the 
solid tumor. In melanoma, glioblastoma, and other solid 
tumors, vascular mimicry in the tumor, which is formed 
directly by the lining of cancer cells, has been found for 
years. Obviously, different manners of forming blood ves-
sels commonly exist at the same time to support tumor 
progression.
We have previously found that at least three types 
of blood vessels exist in clear cell renal cell carcinoma, 
namely, undifferentiated micro-vessels (expressing CD31 
but not CD34 protein in the cells forming micro-vascula-
ture, without pericyte support), immature differentiated 
micro-vessels (expressing both CD31 and CD34 proteins 
on the cells, but not supported by pericytes), and mature 
differentiated vessels (expressing both CD31 and CD34 
proteins, with supporting pericytes partially cover the 
outer layer of the vessels). The mature differentiated ves-
sels are usually co-opted vessels in clear cell renal cell 
carcinoma. However, the origins of the undifferentiated 
as well as the immature differentiated vessels remain 
unclear.
An interesting question is therefore raised: How many 
types of cells can join the formation of effective blood 
conduit for tumor progression? Answering this question 
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Question 24: How tumor cells transmit their 
epigenetic features to daughter cells and maintain 
the malignant phenotype?
Background and implications
It has become increasingly evident that the development 
of tumor involves both genetic and epigenetic changes. 
The term of “epigenetics” refers to machineries that alter 
gene expression without affecting the primary DNA 
sequence, including DNA methylation, histone modi-
fications, and non-coding RNA expression. Epigenetic 
features to some extent associate with the expression pat-
tern of genes that drive cell division and differentiation. 
Altered epigenetic modifications, such as CpG island 
hypermethylation-induced silencing of tumor suppres-
sors, contribute to the malignant phenotype of tumor 
cells. The epigenetic features on chromatin play a cen-
tral role in maintaining transcriptional patterns during 
tumorgenesis. How daughter cells “inherent” epigenetic 
modifications precisely from their predecessor during 
cell division, however, remains largely unknown.
We and Denny Reinberg’s group provided proof of a 
principle that cyclin-dependent kinase 1/2 (CDK1/2) 
phosphorylates enhancer of zeste homolog 2 (EZH2), 
a core component of polycomb repressive complex 2 
(PRC2) catalyzing H3K27me3, at Thr350/345 site dur-
ing cell cycle which facilitates the recruitment of PRC2 
to target locus in a long non-coding RNA-dependent 
manner and establishes H3K27me3 on newly synthesized 
chromatin (1, 2). More answers for this question would 
benefit for the development of new therapeutics that pos-
sibly corrects the altered epigenetic machinery for cancer 
treatment.
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